Overview

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide